Archives

by in
Entry Author Date Location
Madison Startup Rides Immunotherapy Wave With Prostate Drug 08/18/14 Wisconsin
East Coast Biotech Roundup: Acceleron, Seres, Sage, & More 07/18/14 Boston
East Coast Biotech Roundup: Vertex, Cubist, Editas, Polaris, & More 06/27/14 Boston
East Coast Biotech Roundup: Berg, Forma/Celgene, Intarcia, & More 04/04/14 Boston
Oncothyreon Stock Surges on Partner’s Renewed Bet in Lung Cancer 09/25/13 Seattle
Opexa Tries a Personalized Cell Therapy Against Last, Worst Stage of MS 05/02/13 Texas
Merck Bets $15M on Ambrx’s “Smart Bomb” Antibodies 06/18/12 San Diego
Virtual Biotech Companies: Built on Solid Bedrock or Unstable Landfill? 05/03/12 Seattle
Oncothyreon Shares Tumble on Lung Cancer Study Speculation 03/06/12 Seattle
Oncothyreon CEO Bob Kirkman Returns from Medical Leave 12/02/11 Seattle
Idera Regains Cancer Drug Rights From Germany’s Merck; Stock Climbs 11/30/11 Boston
Ambrx Grabs $24M Upfront in New Diabetes, Heart Failure Research Deal With Bristol-Myers 09/22/11 San Diego
Oncothyreon CEO Bob Kirkman Takes Leave, Chairman Chris Henney to Fill In 09/08/11 Seattle
Verizon Buys CloudSwitch, Adimab Inks Biogen and Novo Nordisk Deals, EMD Millpore Buys Amnis, & More Boston-Area Deals News 08/31/11 Boston
Amnis to Be Acquired by EMD Millipore of Merck KGaA 08/30/11 Boston
Amag Eyes Rebound, Idera Surges On Despite Merck KGaA Drop, Verastem Snags $32M, & More Boston-Area Life Sciences News 07/15/11 Boston
Idera Takes Beating on Loss of Merck KGaA Cancer Collaboration, But Remains Committed to Toll-Like Receptors 07/13/11 Boston
Kleiner Perkins’ Bet on a Concrete Stomach, The Gates Foundation’s Out-of-the-Box Ideas, & More Seattle-Area Life Sciences News 05/05/11 Seattle
Biogen Idec Passes Pivotal Trial With Oral MS Drug; Shares Climb 04/11/11 Boston
RXi Sells Stock and Warrants, Cardiorobotics Raises $6.6M, ImmunoGen Dishes On New Drugs, & More Boston-Area Life Sciences News 03/04/11 Boston
FDA Wants More Data on Merck KGaA’s MS Pill As Biogen Develops Rival Therapy 03/02/11 Boston
Clinical Data Stock Surging on FDA Approval of Anti-Depression Drug 01/24/11 Boston
Sproxil Eyes VC Funding and New Customers for Its Technology for Fighting Medication Counterfeiting 01/18/11 Boston
Allozyne Passes First Clinical Trial, Dreams Big About a Once-Monthly Multiple Sclerosis Drug 01/10/11 Seattle
Nano-Terra Takes in $17.2M for Nanotech Development 12/14/10 Boston
Quanterix Adds Former Millipore CEO as Chair 12/01/10 Boston
Allozyne, After a Stealthy Year on a Slim Budget, Re-Emerges with MS Drug and Fat Pipeline 07/14/10 Seattle
Ambrx CEO Steve Kaldor Departs 07/12/10 San Diego
Oncothyreon Lines Up $20M 07/07/10 Seattle
Seattle Genetics’ Dark Horse, Gilead Beats Novartis, Oncothyreon Back in the Saddle, & More Seattle-Area Life Sciences News 06/24/10 Seattle
Page 1 of 3 next page »